Vγ2 x PD-L1 offers promising therapy options for solid tumors, including ovarian cancer (28, 37, 38), melanoma (38, 39), and non-small cell lung cancer (NSCLC) (38). This evidence concerns the gene CD274 and ovarian cancer.